Skip to content

Study · Non-randomized trial · n = 386 · 2017

16 results

Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.

Hamano K, Nishiyama H, Matsui A, Sato M, Takeuchi M

Endocrine journal7 Mar 2017Cited by 12 (Europe PMC)

PMID28302958 (opens in a new tab)DOI10.1507/endocrj.ej16-0428 (opens in a new tab)PepBankPUB-28302958
Source linkPubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the young/high-BMI subgroup, HbA1c changed by -1.48% with dulaglutide.

    In plain wordsIn younger Japanese patients with higher BMI, HbA1c fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c in young/high-BMI subgroup
    Study

    n = 386

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change from baseline
    −1.48%
    young/high-BMI subgroup, week 26

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the young/high-BMI subgroup, weight changed by -0.09 kg with dulaglutide.

    In plain wordsIn younger Japanese patients with higher BMI, weight fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight in young/high-BMI subgroup
    Study

    n = 386

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline
    −0.09 kg
    young/high-BMI subgroup, week 26

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  3. 03HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, nausea incidence with dulaglutide was 7.0% in the young/high-BMI subgroup.

    In plain wordsNausea occurred in 7.0% of younger Japanese patients with higher BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea in young/high-BMI subgroup
    Study

    n = 386

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    7%
    young/high-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  4. 04HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, hypoglycemia incidence with dulaglutide was 8.0% in the young/high-BMI subgroup.

    In plain wordsLow blood sugar occurred in 8.0% of younger Japanese patients with higher BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypoglycemia in young/high-BMI subgroup
    Study

    n = 386

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    8%
    young/high-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  5. 05HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the young/low-BMI subgroup, HbA1c changed by -1.69% with dulaglutide.

    In plain wordsIn younger Japanese patients with lower BMI, HbA1c fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c in young/low-BMI subgroup
    Study

    n = 255

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change from baseline
    −1.69%
    young/low-BMI subgroup, week 26

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  6. 06HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the young/low-BMI subgroup, weight changed by -0.29 kg with dulaglutide.

    In plain wordsIn younger Japanese patients with lower BMI, weight fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight in young/low-BMI subgroup
    Study

    n = 255

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline
    −0.29 kg
    young/low-BMI subgroup, week 26

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  7. 07HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, nausea incidence with dulaglutide was 6.7% in the young/low-BMI subgroup.

    In plain wordsNausea occurred in 6.7% of younger Japanese patients with lower BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea in young/low-BMI subgroup
    Study

    n = 255

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    6.7%
    young/low-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  8. 08HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, hypoglycemia incidence with dulaglutide was 11.0% in the young/low-BMI subgroup.

    In plain wordsLow blood sugar occurred in 11.0% of younger Japanese patients with lower BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypoglycemia in young/low-BMI subgroup
    Study

    n = 255

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    11%
    young/low-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  9. 09HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the elderly/low-BMI subgroup, HbA1c changed by -1.68% with dulaglutide.

    In plain wordsIn older Japanese patients with lower BMI, HbA1c fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c in elderly/low-BMI subgroup
    Study

    n = 137

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change from baseline
    −1.68%
    elderly/low-BMI subgroup

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  10. 10HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the elderly/low-BMI subgroup, weight changed by -0.20 kg with dulaglutide.

    In plain wordsIn older Japanese patients with lower BMI, weight fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight in elderly/low-BMI subgroup
    Study

    n = 137

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline
    −0.2 kg
    elderly/low-BMI subgroup

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  11. 11HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, nausea incidence with dulaglutide was 10.2% in the elderly/low-BMI subgroup.

    In plain wordsNausea occurred in 10.2% of older Japanese patients with lower BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea in elderly/low-BMI subgroup
    Study

    n = 137

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    10.2%
    elderly/low-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  12. 12HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, hypoglycemia incidence with dulaglutide was 18.2% in the elderly/low-BMI subgroup.

    In plain wordsLow blood sugar occurred in 18.2% of older Japanese patients with lower BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypoglycemia in elderly/low-BMI subgroup
    Study

    n = 137

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    18.2%
    elderly/low-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  13. 13HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the elderly/high-BMI subgroup, HbA1c changed by -1.72% with dulaglutide.

    In plain wordsIn older Japanese patients with higher BMI, HbA1c fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c in elderly/high-BMI subgroup
    Study

    n = 77

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change from baseline
    −1.72%
    elderly/high-BMI subgroup

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  14. 14HumanNon-randomized trialEfficacy outcome

    In Japanese T2DM patients in the elderly/high-BMI subgroup, weight changed by -0.26 kg with dulaglutide.

    In plain wordsIn older Japanese patients with higher BMI, weight fell from baseline with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight in elderly/high-BMI subgroup
    Study

    n = 77

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline
    −0.26 kg
    elderly/high-BMI subgroup

    Source sentences

    Summary
    The mean changes from baseline in glycated hemoglobin (HbA1c) and body weight, respectively, were -1.69% and -0.29 kg in the Y/L subgroup; -1.48% and -0.09 kg in the Y/H subgroup; -1.68% and -0.20 kg in the E/L subgroup; and -1.72% and -0.26 kg in the E/H subgroup.
  15. 15HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, nausea incidence with dulaglutide was 3.9% in the elderly/high-BMI subgroup.

    In plain wordsNausea occurred in 3.9% of older Japanese patients with higher BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea in elderly/high-BMI subgroup
    Study

    n = 77

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    3.9%
    elderly/high-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.
  16. 16HumanNon-randomized trialSafety outcome

    In Japanese T2DM patients, hypoglycemia incidence with dulaglutide was 22.1% in the elderly/high-BMI subgroup.

    In plain wordsLow blood sugar occurred in 22.1% of older Japanese patients with higher BMI receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypoglycemia in elderly/high-BMI subgroup
    Study

    n = 77

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    22.1%
    elderly/high-BMI subgroup

    Source sentences

    Summary
    The incidences of nausea and hypoglycemia, respectively, were 6.7% and 11.0% in the Y/L subgroup; 7.0% and 8.0% in the Y/H subgroup; 10.2% and 18.2% in the E/L subgroup; and 3.9% and 22.1% in the E/H subgroup.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.